A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling. iScience. 2023 Sep 1; 107813.
Hackney HJ, Shivram SH, Heiden HJ, Overall OC, Orozco OL, Gao GX, Kim KE, West WN, Qamra QA, Chang CD, Chakrabarti CA, Choy CD, Combes CA, Courau CT, Fragiadakis FG, Rao RA, Ray RA, Tsui TJ, Hu HK, Kuhn KN, Krummel KM, Erle ED, Kangelaris KK, Sarma SA, Lyon LZ, Calfee CC, Woodruff WP, Ghale GR, Mick ME, Byrne BA, Zha ZB, Langelier LC, Hendrickson HC, van der Wijst vM, Hartoularos HG, Grant GT, Bueno BR, Lee LD, Greenland GJ, Sun SY, Perez PR, Ogorodnikov OA, Ward WA, Ye YC, Consortium CU, Ramalingam RT, McBride MJ, Cai CF, Teterina TA, Bao BM, Tsai TL, Rosas RI, Regev RA, Kapadia KS, Bauer BR, Rosenberger RC. .
View in:
Publisher Site Mentions: